MaiaLOBeaussantYGarciaACM. The therapeutic potential of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness: a systematic review. J Pain Symptom Manage2022; 63(6): e725–e738.
2.
Carhart-HarrisRLFristonKJ.REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Barker EL, editor. Pharmacol Rev2019; 71(3): 316–344.
3.
TarbiECMinerSANigamK, et al. “To Have the Encounter with Our Own Finiteness in that Existential Way”: descriptions of existential experience in patients with cancer and major depression participating in psilocybin-assisted group therapy. Psychedelic Med. https://www.liebertpub.com/doi/10.1177/28314425251370303 (2025, accessed 2 September 2025).
BouchetLSagerZYrondiA, et al. Older adults in psychedelic-assisted therapy trials: a systematic review. J Psychopharmacol. 2024; 38: 33–48.
6.
HaftSLDowneyAERaymond-FleschM, et al. A systematic review of participant diversity in psychedelic-assisted psychotherapy trials. Psychiatry Res. 2025; 345: 116359.
7.
BeaussantYTulskyJGuérinB, et al. Mapping an agenda for psychedelic-assisted therapy research in patients with serious illness. J Palliat Med. 2021; 24(11): 1657–1666.
8.
Schwarz-PlaschgC.Socio-psychedelic imaginaries: envisioning and building legal psychedelic worlds in the United States. Eur J Futures Res. 2022; 10(1): 10.
DownarJMacDonaldSBuchmanS.What drives requests for MAiD?CMAJ. 2023; 195(40): E1385–E1387.
11.
MillerMRosaWEDoerner RinaldiA, et al. Applying key lessons from the hospice and palliative care movement to inform psychedelic-assisted therapy. Psychedelic Med. 2023; 1: 124–129.
12.
EmanuelLScandrettK.Decisions at the end of life: have we come of age?BMC Med. 2010; 8(1): 57.